Genmab A/S (GMAB) est une société cotée en bourse dans le Santé secteur, opérant dans le Biotechnologie secteur d'activité. Le siège social de l'entreprise est situé à Copenhagen, Denmark. Le PDG actuel est Jan van de Winkel.
GMAB a date d'introduction en bourse 2009-06-01, 2,638 employés à temps plein, cotée sur le NASDAQ Global Select, une capitalisation boursière de $17.94B.
Genmab A/S is a Danish biopharmaceutical company founded in 1999 that develops antibody-based therapeutics for cancer and other serious diseases. The company's commercial portfolio includes DARZALEX (daratumumab) for multiple myeloma and other blood cancers, teprotumumab for thyroid eye disease, ofatumomab for chronic lymphocytic leukemia and multiple sclerosis, and amivantamab for gastric, esophageal, and lung cancers. Genmab maintains a robust pipeline of clinical and pre-clinical programs, including tisotumab vedotin for solid tumors, epcoritamab for lymphomas, and multiple early-stage candidates in Phase 2 development across oncology and other therapeutic areas. The company partners with leading pharmaceutical and biotech firms including Seagen, AbbVie, Janssen, BioNTech, and Novo Nordisk to advance its research and development efforts globally.
